Physician
Privia Medical Group, LLC
Privia Medical Group, LLC was paid $81.26M by Medicaid between Jan 2018 and Dec 2024, across 389 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 33% of everything it billed.
33Billing provider infoPRIVIA MEDICAL GROUP, LLC
ARLINGTON, VA 22203
ARLINGTON, VA 22203
33aNPI1013042480assigned 02/23/2007
33bProvider typeEndocrinology, Diabetes & Metabolism Physician
28Total paid$81.26M
24GClaims3,633,309
24DCodes billed389
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Endocrinology, Diabetes & Metabolism Physician providers in Virginia
Rank by total paid#1 of 32
Median peer was paid$18K
This provider vs. median4,480×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 112,415 | $3.48M | |
| 2019 | 125,997 | $3.60M | |
| 2020 | 204,938 | $7.93M | |
| 2021 | 511,680 | $12.35M | |
| 2022 | 791,336 | $16.48M | |
| 2023 | 1,012,291 | $20.16M | |
| 2024incomplete | 874,652 | $17.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 33% | 378,886 | 319,174 | $26.53M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 32% | 446,862 | 385,275 | $25.88M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.9% | 16,807 | 16,117 | $1.53M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.6% | 14,801 | 13,543 | $1.27M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 15,325 | 13,774 | $1.20M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.3% | 11,798 | 11,356 | $1.07M |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.1% | 13,414 | 7,231 | $922K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.0% | 9,391 | 7,904 | $822K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 9,063 | 7,405 | $812K |
| 76830 | Ultrasound, transvaginal | <1% | 7,983 | 7,435 | $802K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 9,028 | 8,381 | $798K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 7,131 | 6,787 | $763K |
377 more codes
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 7,073 | $746K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 6,573 | $746K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 6,313 | $641K |
| 87428 | <1% | 18,191 | $634K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 9,111 | $605K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,877 | $603K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14,340 | $513K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,479 | $500K |
| 76820 | <1% | 12,391 | $489K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 37,143 | $480K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 14,645 | $461K |
| 3074F | <1% | 199,656 | $436K | |
| 90686 | <1% | 21,977 | $375K | |
| 58558 | <1% | 282 | $331K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,302 | $328K |
| 3078F | <1% | 163,777 | $325K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 12,044 | $315K |
| 1160F | <1% | 266,140 | $310K | |
| 1159F | <1% | 250,444 | $307K | |
| 99385 | <1% | 2,269 | $276K | |
| 3008F | <1% | 276,600 | $272K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 21,392 | $267K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 18,769 | $257K |
| 1036F | <1% | 271,040 | $229K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,134 | $223K |
| 93000 | <1% | 26,082 | $219K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,533 | $216K |
| 80061 | Lipid panel | <1% | 20,626 | $212K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,101 | $205K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 5,105 | $198K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,269 | $187K |
| 99205 | Prolong outpt/office vis | <1% | 1,899 | $184K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,669 | $183K |
| 76818 | <1% | 1,734 | $170K | |
| 96127 | <1% | 34,087 | $157K | |
| 95819 | <1% | 471 | $151K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,530 | $150K |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 18,726 | $150K |
| 90670 | <1% | 7,023 | $146K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,074 | $142K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 22,066 | $139K |
| 3079F | <1% | 58,612 | $134K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,121 | $119K |
| 80053 | Comprehensive metabolic panel | <1% | 16,946 | $118K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,553 | $115K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 789 | $113K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 633 | $106K |
| 92551 | <1% | 10,529 | $99K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 2,542 | $98K |
| 99386 | <1% | 682 | $97K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,074 | $96K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,606 | $93K |
| 36415 | Collection of venous blood by venipuncture | <1% | 59,347 | $92K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,302 | $87K |
| 99223 | Prolong inpt eval add15 m | <1% | 1,342 | $87K |
| 90698 | <1% | 4,371 | $86K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,070 | $85K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 39 | $84K |
| 3725F | <1% | 68,978 | $80K | |
| 80050 | General health panel | <1% | 6,087 | $77K |
| 0502F | <1% | 45,654 | $75K | |
| 90651 | <1% | 1,899 | $69K | |
| 81025 | <1% | 10,871 | $69K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,198 | $66K |
| 93015 | <1% | 1,896 | $63K | |
| 99459 | <1% | 3,477 | $63K | |
| 99310 | Prolong nursin fac eval 15m | <1% | 4,503 | $62K |
| 81002 | <1% | 28,237 | $61K | |
| 1126F | <1% | 42,534 | $60K | |
| 99460 | <1% | 651 | $59K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 6,035 | $58K |
| 3075F | <1% | 23,601 | $57K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,494 | $57K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,137 | $56K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,644 | $54K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,807 | $52K |
| 3288F | <1% | 29,930 | $49K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,005 | $49K |
| 90633 | <1% | 3,080 | $47K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 759 | $46K |
| 1034F | <1% | 35,556 | $44K | |
| 87807 | <1% | 3,462 | $43K | |
| 84439 | <1% | 6,784 | $42K | |
| 81003 | <1% | 24,419 | $42K | |
| 0011A | <1% | 1,435 | $41K | |
| 0012A | <1% | 1,174 | $40K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,443 | $39K |
| 76825 | <1% | 203 | $39K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 559 | $39K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,434 | $38K |
| 76801 | <1% | 402 | $37K | |
| 1125F | <1% | 23,393 | $37K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 874 | $36K |
| 99173 | <1% | 14,568 | $35K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 641 | $35K |
| 99000 | <1% | 25,827 | $34K | |
| 90680 | <1% | 2,093 | $34K | |
| 90656 | <1% | 2,221 | $33K | |
| 3044F | <1% | 6,669 | $31K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,563 | $31K |
| 82607 | <1% | 2,669 | $29K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 390 | $29K |
| 90677 | <1% | 1,169 | $29K | |
| 94010 | <1% | 2,030 | $28K | |
| 94729 | <1% | 1,308 | $27K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,112 | $27K |
| 90756 | <1% | 1,589 | $26K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 341 | $26K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,347 | $26K |
| 0071A | <1% | 659 | $25K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 979 | $25K |
| 90716 | <1% | 1,144 | $25K | |
| 99174 | <1% | 4,917 | $24K | |
| 0072A | <1% | 585 | $23K | |
| 82746 | <1% | 2,135 | $23K | |
| 3077F | <1% | 11,808 | $22K | |
| 1101F | <1% | 21,939 | $22K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,470 | $21K |
| 90744 | <1% | 1,344 | $21K | |
| 85027 | <1% | 4,017 | $21K | |
| 0064A | <1% | 612 | $21K | |
| 99306 | Prolong nursin fac eval 15m | <1% | 2,057 | $20K |
| 95117 | <1% | 2,787 | $20K | |
| 82728 | <1% | 2,298 | $20K | |
| 90674 | <1% | 1,015 | $20K | |
| 99493 | <1% | 205 | $19K | |
| 82962 | <1% | 11,082 | $19K | |
| 81001 | <1% | 7,376 | $19K | |
| 90707 | <1% | 1,097 | $19K | |
| 0002A | <1% | 515 | $19K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 2,132 | $19K |
| 90723 | <1% | 1,266 | $18K | |
| 90681 | <1% | 909 | $17K | |
| 99442 | <1% | 523 | $16K | |
| 94060 | <1% | 1,354 | $15K | |
| 90710 | <1% | 740 | $15K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 150 | $15K |
| 90619 | <1% | 490 | $14K | |
| 94726 | <1% | 593 | $14K | |
| 83001 | <1% | 833 | $14K | |
| 86803 | <1% | 1,117 | $13K | |
| 82670 | <1% | 580 | $13K | |
| 90715 | <1% | 641 | $13K | |
| 76813 | <1% | 124 | $13K | |
| 0001A | <1% | 367 | $13K | |
| 84481 | <1% | 1,096 | $12K | |
| 99243 | <1% | 143 | $12K | |
| 87210 | <1% | 1,904 | $12K | |
| 90734 | <1% | 522 | $12K | |
| 90697 | <1% | 652 | $12K | |
| 83550 | <1% | 2,202 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,577 | $12K |
| 3080F | <1% | 7,855 | $12K | |
| 90671 | <1% | 453 | $12K | |
| 99457 | <1% | 579 | $12K | |
| 99177 | <1% | 2,903 | $12K | |
| 90648 | <1% | 939 | $12K | |
| 84153 | <1% | 1,016 | $12K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 405 | $11K |
| 97803 | <1% | 319 | $11K | |
| 83002 | <1% | 655 | $11K | |
| 99384 | <1% | 76 | $11K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 118 | $10K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 126 | $9K |
| 83540 | <1% | 2,237 | $9K | |
| 99454 | <1% | 1,026 | $9K | |
| 99494 | <1% | 117 | $9K | |
| 90688 | <1% | 551 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 204 | $9K |
| 85651 | <1% | 2,932 | $9K | |
| 99381 | <1% | 104 | $8K | |
| 96160 | <1% | 3,033 | $8K | |
| 92134 | <1% | 295 | $8K | |
| 90837 | Psychotherapy session, about an hour | <1% | 99 | $8K |
| 99490 | Ccm add 20min | <1% | 1,299 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 96 | $7K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 4,520 | $7K |
| 99072 | <1% | 1,903 | $7K | |
| 83655 | <1% | 638 | $7K | |
| 0124A | <1% | 190 | $7K | |
| 85018 | <1% | 2,859 | $7K | |
| 90647 | <1% | 576 | $6K | |
| 99406 | <1% | 480 | $6K | |
| 99401 | <1% | 358 | $6K | |
| 99383 | <1% | 55 | $6K | |
| 0134A | <1% | 251 | $6K | |
| 51701 | <1% | 231 | $6K | |
| W7000 | <1% | 1,172 | $6K | |
| 99402 | <1% | 180 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,037 | $6K |
| 96161 | <1% | 2,011 | $5K | |
| 54150 | <1% | 124 | $5K | |
| 59025 | Fetal non-stress test | <1% | 202 | $5K |
| 99051 | <1% | 530 | $5K | |
| 85014 | <1% | 2,386 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 181 | $5K |
| 90696 | <1% | 331 | $5K | |
| 0013A | <1% | 142 | $5K | |
| 90661 | <1% | 172 | $5K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 109 | $5K |
| 83735 | <1% | 1,017 | $5K | |
| 69210 | <1% | 120 | $5K | |
| 87634 | <1% | 75 | $5K | |
| 76857 | <1% | 109 | $4K | |
| 97164 | <1% | 308 | $4K | |
| 1035F | <1% | 4,320 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 750 | $4K |
| 11721 | <1% | 332 | $4K | |
| 98927 | <1% | 102 | $4K | |
| 93040 | <1% | 454 | $4K | |
| 80305 | <1% | 485 | $4K | |
| 84146 | <1% | 236 | $4K | |
| 90682 | <1% | 70 | $4K | |
| 92228 | <1% | 169 | $4K | |
| 0004A | <1% | 108 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 71 | $4K |
| 87340 | <1% | 510 | $4K | |
| 86140 | <1% | 897 | $4K | |
| 86580 | <1% | 574 | $4K | |
| 95012 | <1% | 264 | $4K | |
| 84702 | <1% | 597 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 70 | $4K |
| 90685 | <1% | 327 | $4K | |
| 90621 | <1% | 110 | $4K | |
| 3051F | <1% | 657 | $3K | |
| 93325 | <1% | 203 | $3K | |
| 80074 | <1% | 72 | $3K | |
| 99441 | <1% | 493 | $3K | |
| 84550 | <1% | 829 | $3K | |
| 99307 | <1% | 790 | $3K | |
| 82950 | <1% | 615 | $3K | |
| 85610 | <1% | 1,032 | $3K | |
| 76821 | <1% | 39 | $3K | |
| 92250 | <1% | 91 | $3K | |
| 84403 | <1% | 132 | $3K | |
| 87481 | <1% | 93 | $3K | |
| 98928 | <1% | 50 | $2K | |
| 84144 | <1% | 143 | $2K | |
| 85730 | <1% | 748 | $2K | |
| 3046F | <1% | 412 | $2K | |
| 93351 | <1% | 13 | $2K | |
| 99318 | <1% | 116 | $2K | |
| 99458 | <1% | 28 | $2K | |
| 0003A | <1% | 71 | $2K | |
| 95115 | <1% | 222 | $2K | |
| 96040 | <1% | 45 | $2K | |
| 69209 | <1% | 204 | $2K | |
| 31231 | <1% | 14 | $2K | |
| 99050 | <1% | 159 | $2K | |
| 83690 | <1% | 316 | $2K | |
| 93922 | <1% | 19 | $2K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 153 | $2K |
| 57454 | <1% | 12 | $2K | |
| 87631 | <1% | 21 | $2K | |
| 90672 | <1% | 124 | $2K | |
| 94727 | <1% | 110 | $1K | |
| 99305 | <1% | 45 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 175 | $1K |
| 36416 | <1% | 7,318 | $1K | |
| 95923 | <1% | 13 | $1K | |
| 92504 | <1% | 92 | $1K | |
| 64483 | <1% | 12 | $1K | |
| 94760 | <1% | 2,163 | $1K | |
| 81513 | <1% | 43 | $1K | |
| 82150 | <1% | 238 | $1K | |
| G9226 | Foot examination performed (includes examination through visual inspection, sensory exam with 10-g monofilament plus testing any one of the following: vibration using 128-hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold, and pulse exam; report when all of the 3 components are completed) | <1% | 350 | $1K |
| 90620 | <1% | 40 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $1K |
| 91320 | <1% | 15 | $1K | |
| G0136 | Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months | <1% | 175 | $1K |
| 86769 | <1% | 44 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 327 | $1K |
| 3052F | <1% | 231 | $1K | |
| 90662 | <1% | 535 | $985.74 | |
| 97802 | <1% | 14 | $956.13 | |
| 91319 | <1% | 14 | $921.80 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 197 | $921.66 |
| 99070 | <1% | 191 | $876.55 | |
| 17250 | <1% | 17 | $832.51 | |
| 93042 | <1% | 165 | $831.34 | |
| 86706 | <1% | 101 | $820.61 | |
| 99334 | <1% | 109 | $813.16 | |
| 95921 | <1% | 13 | $812.64 | |
| 86705 | <1% | 135 | $810.00 | |
| 86709 | <1% | 133 | $785.32 | |
| 90700 | <1% | 65 | $748.30 | |
| 58300 | <1% | 14 | $727.43 | |
| 92587 | <1% | 43 | $714.00 | |
| 90687 | <1% | 29 | $675.12 | |
| 82951 | <1% | 67 | $640.94 | |
| 90480 | <1% | 27 | $636.56 | |
| 64484 | <1% | 12 | $623.68 | |
| 91322 | <1% | 15 | $615.65 | |
| 82947 | <1% | 250 | $603.67 | |
| 57465 | <1% | 12 | $596.76 | |
| 82550 | <1% | 118 | $577.44 | |
| 87430 | <1% | 52 | $570.86 | |
| H1000 | Prenatal care, at-risk assessment | <1% | 14 | $560.00 |
| 98926 | <1% | 14 | $556.70 | |
| 99496 | <1% | 15 | $547.91 | |
| 81000 | <1% | 169 | $543.36 | |
| 90673 | <1% | 14 | $527.93 | |
| 84480 | <1% | 50 | $523.21 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 547 | $501.38 |
| 0081A | <1% | 12 | $480.00 | |
| 0154A | <1% | 12 | $480.00 | |
| 83721 | <1% | 59 | $473.57 | |
| 90694 | <1% | 90 | $452.30 | |
| 0074A | <1% | 13 | $440.00 | |
| 82977 | <1% | 75 | $435.23 | |
| 90461 | <1% | 1,019 | $429.63 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 335 | $411.10 |
| 88141 | <1% | 52 | $380.69 | |
| 62323 | <1% | 13 | $378.54 | |
| 94664 | <1% | 28 | $364.25 | |
| 87625 | <1% | 17 | $334.40 | |
| 92202 | <1% | 26 | $329.01 | |
| 80076 | <1% | 145 | $324.79 | |
| 92083 | <1% | 12 | $322.66 | |
| 85652 | <1% | 141 | $304.08 | |
| 99348 | <1% | 45 | $290.81 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $288.12 |
| 92567 | <1% | 25 | $272.27 | |
| 93356 | <1% | 27 | $221.91 | |
| 74018 | <1% | 12 | $217.17 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 65 | $215.47 |
| 87808 | <1% | 20 | $206.72 | |
| 99397 | <1% | 28 | $205.76 | |
| 82952 | <1% | 54 | $191.68 | |
| 88142 | <1% | 13 | $186.38 | |
| 85049 | <1% | 108 | $169.87 | |
| 92015 | Determination of refractive state | <1% | 15 | $163.89 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 42 | $163.15 |
| 86308 | <1% | 37 | $152.32 | |
| 1220F | <1% | 26 | $150.00 | |
| 0501F | <1% | 40 | $150.00 | |
| 95251 | <1% | 160 | $149.16 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 197 | $144.47 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 135 | $140.43 |
| 0503F | <1% | 229 | $130.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 14 | $124.44 |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 105 | $97.33 |
| 99080 | <1% | 16 | $95.01 | |
| 93297 | <1% | 24 | $64.15 | |
| 1100F | <1% | 830 | $50.00 | |
| 82043 | <1% | 15 | $49.30 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 38 | $46.71 |
| 99001 | <1% | 89 | $40.00 | |
| 90474 | <1% | 15 | $28.24 | |
| 99453 | <1% | 27 | $28.23 | |
| 2023F | <1% | 26 | $25.00 | |
| 99439 | <1% | 63 | $22.85 | |
| 20610 | <1% | 13 | $22.31 | |
| A9150 | Non-prescription drugs | <1% | 106 | $17.20 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 13 | $17.16 |
| 85008 | <1% | 97 | $17.14 | |
| 99335 | <1% | 40 | $12.95 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 178 | $12.78 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 27 | $6.86 |
| 85007 | <1% | 18 | $3.80 | |
| 91301 | <1% | 98 | $0.73 | |
| 91307 | <1% | 92 | $0.19 | |
| 91306 | <1% | 29 | $0.17 | |
| 91313 | <1% | 22 | $0.16 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 304 | $0.08 |
| 91312 | <1% | 17 | $0.08 | |
| 91300 | <1% | 15 | $0.06 | |
| 99499 | <1% | 8,029 | $0.05 | |
| 1111F | 0% | 126 | $0.00 | |
| 2033F | 0% | 66 | $0.00 | |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | 0% | 12 | $0.00 |
| 2028F | 0% | 198 | $0.00 | |
| 99188 | 0% | 61 | $0.00 | |
| 99199 | Unlisted special service, procedure or report | 0% | 232 | $0.00 |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | 0% | 150 | $0.00 |
| 99497 | 0% | 19 | $0.00 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOULKROD, BRIANNA (AVP CREDENTIALING AND ENROLLMENT)